Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025203 | 0.85 | HDAC3 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12581692 | 0.83 | MAPT (0.35) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL2866529 | 0.83 | HDAC3 (0.32) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17385919 | 0.83 | ALDH1A1 (0.39) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL28859118 | 0.82 | DPP4 (0.33) | PDE4APDE4BPDE4CPDE4DFYN | |
| SCHEMBL4394914 | 0.81 | HSD17B10 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2859836 | 0.80 | HSP90AB1 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4378992 | 0.78 | F2 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL16010033 | 0.77 | ALDH1A1 (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3155410 | 0.77 | MAPT (0.37) | PDE4APDE4BPDE4CPDE4DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343944-B2 | Trisubstituted boron-containing molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343944-B2 | Trisubstituted boron-containing molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343944-B2 | Trisubstituted boron-containing molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2458995-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20110136763-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136763-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136763-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7781485-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070265268-A1 | Hsp90 Family protein Inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1813270-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265268-A1 | Hsp90 Family protein Inhibitors | HSPA4L, HSP90AB1, HSP90B1 | PDE4A 3857/4885PDE4B 4231/4885PDE4C 4367/4885 |
| US-20110136763-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | BCL6B, BCL6, BLK | PDE4A 3536/4885PDE4B 2164/4885PDE4C 3534/4885 |
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | PDE4A 4374/4885PDE4B 4266/4885PDE4C 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.